NEW YORK (GenomeWeb) – Agendia and CBLPath today announced a collaboration to provide molecular diagnostic testing to breast cancer patients.
CBLPath provides pathology services with a large focus on breast cancer, Agendia CMO Neil Barth said, while his firm offers the MammaPrint test for breast cancer recurrence and the BluePrint assay for molecular subtyping of breast cancer. "By working closely together, Agendia and CBLPath will move the treatment of breast cancer toward better outcomes and fewer unnecessary side effects," he said in a statement.
CBLPath Co-CEO and Chief Medical Officer Carlos Urmacher added that his firm's expertise in breast pathology "coupled with Agendia's innovative tests will provide definitive information for breast cancer patients and their physicians when evaluating treatment options."
Financial and other terms of the deal were not disclosed.
Last month CBLPath announced an agreement with the University of Pittsburgh Medical Center Division of Molecular and Genomic Pathology covering next-generation sequencing-based thyroid cancer testing.